GCL
NAUT icon

Glazer Capital LLC’s Nautilus Biotechnolgy NAUT Stock Holding History

Glazer Capital LLC’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-320,017
Closed -$3.47M – 762
2020
Q4 		$3.47M Sell
320,017
-14,221
-4% -$150K 0.12% 177
2020
Q3 		$3.62M Buy
+334,238
New +$3.57M 0.18% 131

Other funds holding NAUT

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Glazer Capital LLC's NAUT Position: Q1 2021 in Review

Glazer Capital LLC sold out of Nautilus Biotechnolgy (NAUT) in Q1 2021, closing a stake of 320,017 shares — an estimated $3.47M sold.

Glazer Capital LLC first reported a position in NAUT in Q3 2020 and held it in 2 quarters. The position peaked at $3.62M in Q3 2020. 44 funds tracked by Wall St. Rank hold NAUT as of Q1 2021.

  • Glazer Capital LLC reported no remaining Nautilus Biotechnolgy position as of Q1 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 320,017 Nautilus Biotechnolgy shares in Q1 2021, an estimated $3.47M.
  • Glazer Capital LLC first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 2 quarters.
  • Glazer Capital LLC's Nautilus Biotechnolgy position peaked at $3.62M in Q3 2020.
  • 44 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2021.

Based on Glazer Capital LLC's 13F filing for Q1 2021, filed 14 May 2021.